Publicaties

<<<< terug naar Klinische informatie

  • Sally Irving
    Managing chronic, nonhealing wounds stalled in the inflammatory phase:
    a case series using a novel matrix therapy, CACIPLIQ20. British Journal of community nursing September 2019

  • Sharifah Ahmad Roohi & Denis Barritault. ReGeneraTing Agents (RGTA®): A new option for healing and improving treatment outcomes for traumatic and burn injuries of the hand. Clin Case Rep. 2019;1–9 DOI: 10.1002/ccr3.2054

  • Roohi Sharifah Ahmad & Denis Barritault ReGeneraTing Agents (RGTA®) are a new option to improve amputation outcomes in the recovery of severe hand injuries Clin Case Rep. 2018;1–9. DOI: 10.1002/ccr3.1797

  • Papanas N,. Demetzos C., Pippa N., Maltezos E, and Tentolouris, N. Efficacy of a new Heparan sulfate mimetic dressing in the healing of foot and lower extremity ulceration in type 2 diabetes. The International Journal of Lower Extremity Wounds. 2016,15,63-7

  • Roohi SA* and Barritault Use of the Regenerating Agent CACIPLIQ20 in the repair and regeneration of mostly upper extremity ischaemic wounds: A prospective pilot study. Proceedings of the APFSSH (Asia Pacific Society for Surgery of the Hand) 10th Congress 2-4th Oct 2014)

  • Hayek S, Dibo S, Baroud J, Ibrahim A, Barritault D. Refractory sickle cell leg ulcer: is heparan sulphate a new hope?. Int Wound J 2014; doi: 10.1111/iwj.12217 Article first published online: 21 FEB 2014

  • Shady Hayek, Elias Zgheib, Bishara Atieh: Steward Bluefarb Syndrome: Review of the literature and case report of chronic ulcer treatment with heparan sulfate mimetic  (CACIPLIQ 20®) International Wound Journal 2013 Vol 5 p DOI: 10.1111/iwj.12074 

  • Slim I, Tajouri H, Barritault D, Kacem M, Ach K, Chadli-Chaieb, M Chaieb L, Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLIQ20 Journal of Wound Technology, 2012, 16-20

  • D. Barritault, S. Al Harbi , S. Filipe Garcia, V. Plassat et G. Zakine La thérapie matricielle une nouvelle branche de la médecine régénérative et ses applications dans le traitement des brulés : Du fondamental à la clinique. Brulure , 2012,13,23-27

  • Ali Al Malaq and Denis Barritault A rapid response to matrix therapy with RGTA in severe epidermolysis bullosa, Eplasty 2012;12:e47. Epub 2012 Sep 12.

  • Pascal Desgranges, Taïna Louissaint, Eric Allaire, Bertrand Godeau, Ketty Kichenin Jean- Pierre Becquemin and  Denis Barritault. First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA®) technology Journal of Wound Technology, 13:44-48, 2011

  • Van Neck JW, Zuidema YS, Smulders M, Balmus KJ. Unexpected healing of radiation-induced scalp lesions with OTR4120, a heparan sulfate mimetic.  Eur J Dermatol. 2011 May 20.

  • Groah S L, Libin A,  Spungen M, Nguyen Kim-Loan, Woods E, Nabili M, Ramella-Roman J, Barritault D. Regenerating matrix-based therapy for chronic wound healing: A prospective within-subject pilot study. Int. Wound J. 2011 Feb;8(1):85-95

  • Zakine G, Le Louarn C. [First applications of matrix therapy in plastic and aesthetic surgery]. Ann Chir Plast Esthet. 2010 Oct;55(5):421-8. doi:  10.1016/j.anplas.2010.07.011.. French.

Publicaties
Via onderstaande links komt u terecht op de online bibliotheek van het Amerikaanse National Institute of Health. U leest daar meer over onderzoek naar regenerating agents en gerelateerde onderwerpen. 

Johan van Neck, Bastiaan Tuk, Denis Barritault and Miao Tong, Heparan Sulfate Proteoglycan Mimetics Promote Tissue Regeneration: An Overview

Tong M, Tuk B, Hekking I, Vermeij M, Barritault D, Van Neck J. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120.Wound Rep Reg (2009) 17 840–852. 

Barbier-Chassefière V, Garcia-Filipe S, Yue Xl, Kerros Me, Petit E, Kern P, Saffar Jl, Papy-Garcia D, Caruelle JP and Barritault D. Matrix Therapy and regenerative medicine, a new approach for chronic wound healing. J Biomed Mater Res A. 2008, in press.

Tong M, Zbinden MM, Hekking IJ, Vermeij M, Barritault D, van Neck JW. RGTA OTR 4120, a heparan sulphate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds. Wound Repair and Regeneration. 2008, 16, 294-299.

Garcia-Filipe S, Barbier-Chassefiere V, Alexakis C, Huet C, Ledoux D, Kerros ME, Petit E, Barritault D, Caruelle JP, Kern P. RGTA OTR4120, a heparan sulfate mimetic is a possible long-term active agent to heal burned skin.” J Biomed Mater Res. 2007, 80(1):75-84.

Barritault D, Caruelle JP. Regenerating agents (RGTAs): a new therapeutic approach. Ann Pharm Fr. 2006 64(2):135-44.

Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem. 2005, 280(38):32792-800.

Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot MA, Barritault D, Caruelle JP, Kern P. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1. FASEB J. 2004, 18(10):1147-9.

Alexakis C, Strup C, Mestries P, Mathe D, Caruelle JP, Barritault D, Kern P. Regulation of the collagen phenotype expression of gamma-irradiated vascular smooth muscle cells by heparan mimetics (RGTA)”. J Biomed Mater Res A. 2004, 70(4):594-602.

First clinical pilot study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA) Technology - July 2011

Matrix protection therapy in vascular disease

Abstract matrix protection therapy in diabetic foot ulcers

First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy Regenerating Agent (RGTA) technology

Diabetes-Impaired Wound Healing Is Improved by Matrix Therapy with Heparan Sulfate Glycosaminoglycan Mimetic OTR4120 in Rats 

A rapid response to matrix therapy with RGTA® in severe epidermolysis bullosa

Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLQ20

Onderstaande document bevat diverse onderzoeken naar en onderzoeksresultaten over de werking van caciplig20® en regenerating agents technologie die u ook kunt vinden op www.pubmed.gov

Selectie van gepubliceerde artikelen over RGTA-technologie 1999-2012.